Skip to main navigation

Investors
News Releases
Events & Presentations
Stock Information
Corporate Governance
SEC Filings
IR Resources

News Releases

News Releases

Year

May 9, 2019

Harpoon Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update

April 18, 2019

Harpoon Therapeutics Doses First Patient with a Mesothelin-Targeting T cell Engager (HPN536) in Phase 1/2a Clinical Trial for Ovarian and Other Solid Tumor Cancers

March 14, 2019

Harpoon Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update

March 13, 2019

Harpoon Therapeutics to Participate in Upcoming William Blair Cancer Immunotherapy Conference

March 7, 2019

Harpoon Therapeutics to Report Fourth Quarter and Full Year 2018 Financial Results

February 20, 2019

Harpoon Therapeutics to Present at SVB Leerink Global Healthcare Conference

February 7, 2019

Harpoon Therapeutics Announces Pricing of Initial Public Offering

January 2, 2019

Harpoon Therapeutics Announces Preliminary Safety and Pharmacology Data from its HPN424 Phase 1 Trial in Prostate Cancer

December 27, 2018

Harpoon Therapeutics Announces Filing of Registration Statement for Proposed Initial Public Offering

December 2, 2018

Harpoon Therapeutics Presents Preclinical Data Supporting Development of HPN217, a New BCMA-Targeting TriTAC, at the 2018 American Society of Hematology (ASH) Annual Meeting

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Email Alerts

RSS Feeds

Contact IR

Search

© 2019. Harpoon Therapeutics, Inc. All rights reserved.

Search Investor Relations